Jonathan Pai
Hematology & Oncology · Walnut Creek, CANPI 1285196105
Payments from drug & device makers
Across 202 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$514
- Novartis$497
- Merck$452
- AbbVie$437
- Incyte Corporation$430
- Bristol Myers Squibb$344
- plus $3K from 34 others
What the payments were for
- Food & beverage$4,93795%
- Education$2655%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 22 | $514 |
| Novartis | 25 | $497 |
| Merck | 18 | $452 |
| AbbVie | 19 | $437 |
| Incyte Corporation | 13 | $430 |
| Bristol Myers Squibb | 13 | $344 |
| AstraZeneca(2 entities) | 12 | $273 |
| EMD Serono, Inc. | 5 | $194 |
| Sobi, Inc | 3 | $179 |
| Daiichi Sankyo Inc. | 7 | $173 |
| Servier Pharmaceuticals LLC | 7 | $173 |
| Pfizer | 5 | $152 |
| Johnson & Johnson | 5 | $113 |
| Ipsen Biopharmaceuticals, Inc | 4 | $101 |
| Blueprint Medicines Corporation | 3 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $88 |
| Jazz Pharmaceuticals Inc. | 3 | $83 |
| Genentech USA, Inc. | 3 | $83 |
| Amgen | 3 | $73 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Deciphera Pharmaceuticals Inc. | 3 | $66 |
| Geron Corporation | 2 | $59 |
| GSK | 2 | $58 |
| Karyopharm Therapeutics Inc. | 2 | $54 |
| Agios Pharmaceuticals, Inc. | 2 | $47 |
| Eisai Inc. | 2 | $45 |
| Stemline Therapeutics Inc. | 1 | $40 |
| Gilead | 1 | $34 |
| Exelixis Inc. | 1 | $32 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| Genmab U.S., Inc. | 1 | $29 |
| Seagen Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Beigene USA, Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Gamifant$122
How this compares
$5,202 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 11 | $131 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Walnut Creek
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.